Latest Updates

    None Found

Open-label Add-on Treatment Trial of Minocycline in Fragile X Syndrome


Results from this study demonstrate that minocycline provides significant functional benefits to FXS patients and that it is well-tolerated. These findings are consistent with the fmr1 knockout mouse model results, suggesting that minocycline modifies underlying neural defects that account for behavioural abnormalities. A placebo-controlled trial of minocycline in FXS is warranted. Trial registration: Open-Label Trial NCT00858689

»Continue Reading Abstract«



Originally posted on BioMed Central.

Comments are closed.